Orthogonally Functionalized Nanoscale Micelles for Active Targeted Codelivery of Methotrexate and Mitomycin C with Synergistic Anticancer Effect

Molecular Pharmaceutics

Volumn 12, Issue 3, 2015, Pages 769-782

  Li, Yang ^a   Lin, Jinyan ^a   Wu, Hongjie ^a   Chang, Ying ^a   Yuan, Conghui ^a   Liu, Cheng ^a   Wang, Shuang ^a   Hou, Zhenqing ^a   Dai, Lizong ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

combination cancer chemotherapy; methotrexate; micelles; mitomycin C; targeted drug delivery

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N METHOXY(POLYETHYLENE GLYCOL) 3000; METHOTREXATE; MITOMYCIN; NANOCARRIER; POLYMER; UNCLASSIFIED DRUG; 1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE; NANOCAPSULE; PHOSPHATIDYLETHANOLAMINE;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG TRANSPORT; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG SCREENING; METABOLISM; MICELLE; NANOTECHNOLOGY; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; PHARMACEUTICS; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOPHARMACEUTICS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FEMALE; HELA CELLS; HUMANS; METHOTREXATE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; MITOMYCIN; NANOCAPSULES; NANOTECHNOLOGY; NEOPLASMS, EXPERIMENTAL; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924069877     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5006068     Document Type: Article

References (58)

1. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007, 2, 751-760
2. Cho, E. J.; Holback, H.; Liu, K. C.; Abouelmagd, S. A.; Park, J.; Yeo, Y. Nanoparticle characterization: state of the art, challenges, and emerging technologies Mol. Pharmaceutics 2013, 10, 2093-2110
3. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics CA Cancer J. Clin. 2011, 61, 69-90
4. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-674
5. Woodcock, J.; Griffin, J. P.; Behrman, R. E. Development of novel combination therapies N. Engl. J. Med. 2011, 364, 985-987
6. Lehar, J.; Krueger, A. S.; Avery, W.; Heilbut, A. M.; Johansen, L. M.; Price, E. R.; Rickles, R. J.; Short, G. F., 3rd; Staunton, J. E.; Jin, X.; Lee, M. S.; Zimmermann, G. R.; Borisy, A. A. Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat. Biotechnol. 2009, 27, 659-666
7. Kaelin, W. G., Jr. The concept of synthetic lethality in the context of anticancer therapy Nat. Rev. Cancer 2005, 5, 689-698
8. Yao, J.; Zhang, L.; Zhou, J.; Liu, H.; Zhang, Q. Efficient Simultaneous Tumor Targeting Delivery of All-Trans Retinoid Acid and Paclitaxel Based on Hyaluronic Acid-Based Multifunctional Nanocarrier Mol. Pharmaceutics 2013, 10, 1080-1091
9. Liao, L.; Liu, J.; Dreaden, E. C.; Morton, S. W.; Shopsowitz, K. E.; Hammond, P. T.; Johnson, J. A. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of Cisplatin, Doxorubicin, and camptothecin J. Am. Chem. Soc. 2014, 136, 5896-5899
10. Chen, Y.; Chen, H.; Shi, J. Inorganic nanoparticle-based drug codelivery nanosystems to overcome the multidrug resistance of cancer cells Mol. Pharmaceutics 2014, 11, 2495-2510
11. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance Nature 2000, 406, 775-781
12. Kratz, F.; Warnecke, A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems J. Controlled Release 2012, 164, 221-235
13. Kolishetti, N.; Dhar, S.; Valencia, P. M.; Lin, L. Q.; Karnik, R.; Lippard, S. J.; Langer, R.; Farokhzad, O. C. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 17939-17944
14. Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial drug therapy for cancer in the post-genomic era Nat. Biotechnol. 2012, 30, 679-692
15. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 2010, 328, 1031-1035
16. Iyer, V. N.; Szybalski, W. Mitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-Linking of DNA Science 1964, 145, 55-58
17. Maitra, R.; Halpin, P. A.; Karlson, K. H.; Page, R. L.; Paik, D. Y.; Leavitt, M. O.; Moyer, B. D.; Stanton, B. A.; Hamilton, J. W. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression Biochem. J. 2001, 355, 617-624
18. Ekins, S.; Kim, R. B.; Leake, B. F.; Dantzig, A. H.; Schuetz, E. G.; Lan, L.-B.; Yasuda, K.; Shepard, R. L.; Winter, M. A.; Schuetz, J. D.; Wikel, J. H.; Wrighton, S. A. Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein Mol. Pharmacol. 2002, 61, 964-973
19. Gabizon, A. A.; Tzemach, D.; Horowitz, A. T.; Shmeeda, H.; Yeh, J.; Zalipsky, S. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes Clin. Cancer Res. 2006, 12, 1913-1920
20. Rumpf, K. W.; Rieger, J.; Lankisch, P. G.; von Heyden, H. W.; Nagel, G. A.; Scheler, F. Mitomycin-induced haemolysis and renal failure Lancet 1980, 2, 1037-1038
21. Chabner, B. A.; Roberts, T. G., Jr. Timeline: Chemotherapy and the war on cancer Nat. Rev. Cancer 2005, 5, 65-72
22. Morton, A. R.; Anderson, H.; Howell, A. Myelotoxicity of methotrexate, mitozantrone, and mitomycin C Lancet 1987, 1, 1494
23. Rijnboutt, S.; Jansen, G.; Posthuma, G.; Hynes, J. B.; Schornagel, J. H.; Strous, G. J. Endocytosis of GPI-linked membrane folate receptor-alpha J. Cell Biol. 1996, 132, 35-47
24. Chen, C.; Ke, J.; Zhou, X. E.; Yi, W.; Brunzelle, J. S.; Li, J.; Yong, E. L.; Xu, H. E.; Melcher, K. Structural basis for molecular recognition of folic acid by folate receptors Nature 2013, 500, 486-489
25. Li, Y.; Lin, J.; Wu, H.; Jia, M.; Yuan, C.; Chang, Y.; Hou, Z.; Dai, L. Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C J. Mater. Chem. B 2014, 2, 6534-6548
26. Rogachev, A. Y.; Hoffmann, R. Iodine (I2) as a Janus-faced ligand in organometallics J. Am. Chem. Soc. 2013, 135, 3262-3275
27. Dopieralski, P.; Ribas-Arino, J.; Anjukandi, P.; Krupicka, M.; Kiss, J.; Marx, D. The Janus-faced role of external forces in mechanochemical disulfide bond cleavage Nat. Chem. 2013, 5, 685-691
28. Wilson, S. B.; Delovitch, T. L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity Nat. Rev. Immunol. 2003, 3, 211-222
29. Shi, J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications Nano Lett. 2010, 10, 3223-3230
30. Wei, T.; Liu, J.; Ma, H.; Cheng, Q.; Huang, Y.; Zhao, J.; Huo, S.; Xue, X.; Liang, Z.; Liang, X. J. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo Nano Lett. 2013, 13, 2528-2534
31. Sethi, V.; Rubinstein, I.; Kuzmis, A.; Kastrissios, H.; Artwohl, J.; Onyuksel, H. Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis Mol. Pharmaceutics 2013, 10, 728-738
32. Torchilin, V. P. PEG-based micelles as carriers of contrast agents for different imaging modalities Adv. Drug Delivery Rev. 2002, 54, 235-252
33. Tang, N.; Du, G.; Wang, N.; Liu, C.; Hang, H.; Liang, W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin J. Natl. Cancer Inst. 2007, 99, 1004-1015
34. Hou, Z.; Li, Y.; Huang, Y.; Zhou, C.; Lin, J.; Wang, Y.; Cui, F.; Zhou, S.; Jia, M.; Ye, S.; Zhang, Q. Phytosomes loaded with mitomycin C-soybean phosphatidylcholine complex developed for drug delivery Mol. Pharmaceutics 2013, 10, 90-101
35. Khan, J.; Alexander, A.; Ajazuddin; Saraf, S.; Saraf, S. Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives J. Controlled Release 2013, 168, 50-60
36. Wu, C.; Zhang, M.; Zhang, Z.; Wan, K. W.; Ahmed, W.; Phoenix, D. A.; Elhissi, A. M.; Sun, X. Thymopentin Nanoparticles Engineered with High Loading Efficiency, Improved Pharmacokinetic Properties, and Enhanced Immunostimulating Effect Using Soybean Phospholipid and PHBHHx Polymer Mol. Pharmaceutics 2014, 11, 3371-3377
37. Li, Y.; Wu, H.; Yang, X.; Jia, M.; Li, Y.; Huang, Y.; Lin, J.; Wu, S.; Hou, Z. Mitomycin C-Soybean Phosphatidylcholine Complex-Loaded Self-Assembled PEG-Lipid-PLA Hybrid Nanoparticles for Targeted Drug Delivery and Dual-Controlled Drug Release Mol. Pharmaceutics 2014, 11, 2915-2927
38. Li, Y.; Wu, H.; Jia, M.; Cui, F.; Lin, J.; Yang, X.; Wang, Y.; Dai, L.; Hou, Z. Therapeutic Effect of Folate-Targeted and PEGylated Phytosomes Loaded with a Mitomycin C-Soybean Phosphatidyhlcholine Complex Mol. Pharmaceutics 2014, 11, 3017-3026
39. Qin, C.; He, B.; Dai, W.; Zhang, H.; Wang, X.; Wang, J.; Zhang, X.; Wang, G.; Yin, L.; Zhang, Q. Inhibition of metastatic tumor growth and metastasis via targeting metastatic breast cancer by chlorotoxin-modified liposomes Mol. Pharmaceutics 2014, 11, 3233-3241
40. Wu, J.; Jiang, H.; Bi, Q.; Luo, Q.; Li, J.; Zhang, Y.; Chen, Z.; Li, C. Apamin-mediated actively targeted drug delivery for treatment of spinal cord injury: more than just a concept Mol. Pharmaceutics 2014, 11, 3210-3222
41. Yan, Z.; Yang, Y.; Wei, X.; Zhong, J.; Wei, D.; Liu, L.; Xie, C.; Wang, F.; Zhang, L.; Lu, W.; He, D. Tumor-penetrating peptide mediation: an effective strategy for improving the transport of liposomes in tumor tissue Mol. Pharmaceutics 2014, 11, 218-225
42. Bharali, D. J.; Lucey, D. W.; Jayakumar, H.; Pudavar, H. E.; Prasad, P. N. Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy J. Am. Chem. Soc. 2005, 127, 11364-11371
43. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharmaceutics 2008, 5, 505-515
44. Cheetham, A. G.; Zhang, P.; Lin, Y. A.; Lock, L. L.; Cui, H. Supramolecular nanostructures formed by anticancer drug assembly J. Am. Chem. Soc. 2013, 135, 2907-2910
45. Poole, A. R.; Tiltman, K. J.; Recklies, A. D.; Stoker, T. A. M. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas Nature 1978, 273, 545-547
46. Weissleder, R.; Tung, C. H.; Mahmood, U.; Bogdanov, A., Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes Nat. Biotechnol. 1999, 17, 375-378
47. Thomas, T. P.; Huang, B.; Choi, S. K.; Silpe, J. E.; Kotlyar, A.; Desai, A. M.; Zong, H.; Gam, J.; Joice, M.; Baker, J. R., Jr. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic Mol. Pharmaceutics 2012, 9, 2669-2676
48. Lachelt, U.; Wittmann, V.; Muller, K.; Edinger, D.; Kos, P.; Hohn, M.; Wagner, E. Synthetic Polyglutamylation of Dual-Functional MTX Ligands for Enhanced Combined Cytotoxicity of Poly(I:C) Nanoplexes Mol. Pharmaceutics 2014, 11, 2631-2639
49. Luo, F.; Li, Y.; Jia, M.; Cui, F.; Wu, H.; Yu, F.; Lin, J.; Yang, X.; Hou, Z.; Zhang, Q. Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro Nanoscale Res. Lett. 2014, 9, 363
50. Rai, P.; Padala, C.; Poon, V.; Saraph, A.; Basha, S.; Kate, S.; Tao, K.; Mogridge, J.; Kane, R. S. Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins Nat. Biotechnol. 2006, 24, 582-586
51. Irvine, D. J. Drug delivery: One nanoparticle, one kill Nat. Mater. 2011, 10, 342-343
52. Jiang, W.; KimBetty, Y. S.; Rutka, J. T.; ChanWarren, C. W. Nanoparticle-mediated cellular response is size-dependent Nat. Nanotechnol. 2008, 3, 145-150
53. Licata, N. A.; Tkachenko, A. V. Kinetic limitations of cooperativity-based drug delivery systems Phys. Rev. Lett. 2008, 100, 158102-158105
54. Martinez-Veracoechea, F. J.; Frenkel, D. Designing super selectivity in multivalent nano-particle binding Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 10963-10968
55. Pastan, I.; Hassan, R.; Fitzgerald, D. J.; Kreitman, R. J. Immunotoxin therapy of cancer Nat. Rev. Cancer 2006, 6, 559-565
56. Barua, S.; Mitragotri, S. Synergistic Targeting of Cell Membrane, Cytoplasm, and Nucleus of Cancer Cells Using Rod-Shaped Nanoparticles ACS Nano 2013, 7, 9558-9570
57. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
58. Shah, N. B.; Vercellotti, G. M.; White, J. G.; Fegan, A.; Wagner, C. R.; Bischof, J. C. Blood-Nanoparticle Interactions and in Vivo Biodistribution: Impact of Surface PEG and Ligand Properties Mol. Pharmaceutics 2012, 2146-2155